TY - JOUR
T1 - The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes
AU - Dendooven, Amélie
AU - Nguyen, Tri Q.
AU - Brosens, Lodewijk
AU - Li, Dongxia
AU - Tarnow, Lise
AU - Parving, Hans Henrik
AU - Rossing, Peter
AU - Goldschmeding, Roel
PY - 2011/5/10
Y1 - 2011/5/10
N2 - The -945GC polymorphism (rs6918698) in the connective tissue growth factor gene promoter (CTGF/CCN-2) has been associated with end organ damage in systemic sclerosis. Because CTGF is important in progression of diabetic kidney disease, we investigated whether the -945GC polymorphism is associated with plasma CTGF level and outcome in type 1 diabetes. The study cohort consisted of 448 diabetic nephropathy patients and 419 normoalbuminuric diabetic patients with complete data concerning renal function and cardiovascular characteristics. Genomic DNA was genotyped by a QPCR-based SNP assay. We observed no relation between the -945GC polymorphism and plasma CTGF level, and the genotype frequencies were not different in nephropathy patients vs. normoalbuminuric controls. General and cardiovascular mortality, and renal function decline was similar in patients with CC, CG or GG genotypes. In conclusion, the -945GC SNP does not affect plasma CTGF levels, incidence and prognosis of diabetic nephropathy, and cardiovascular outcome.
AB - The -945GC polymorphism (rs6918698) in the connective tissue growth factor gene promoter (CTGF/CCN-2) has been associated with end organ damage in systemic sclerosis. Because CTGF is important in progression of diabetic kidney disease, we investigated whether the -945GC polymorphism is associated with plasma CTGF level and outcome in type 1 diabetes. The study cohort consisted of 448 diabetic nephropathy patients and 419 normoalbuminuric diabetic patients with complete data concerning renal function and cardiovascular characteristics. Genomic DNA was genotyped by a QPCR-based SNP assay. We observed no relation between the -945GC polymorphism and plasma CTGF level, and the genotype frequencies were not different in nephropathy patients vs. normoalbuminuric controls. General and cardiovascular mortality, and renal function decline was similar in patients with CC, CG or GG genotypes. In conclusion, the -945GC SNP does not affect plasma CTGF levels, incidence and prognosis of diabetic nephropathy, and cardiovascular outcome.
UR - http://www.scopus.com/inward/record.url?scp=79955657088&partnerID=8YFLogxK
U2 - 10.1186/1477-5751-10-4
DO - 10.1186/1477-5751-10-4
M3 - Article
C2 - 21548990
AN - SCOPUS:79955657088
SN - 1477-5751
VL - 10
JO - Journal of Negative Results in BioMedicine
JF - Journal of Negative Results in BioMedicine
IS - 1
M1 - 4
ER -